<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054482</url>
  </required_header>
  <id_info>
    <org_study_id>FAHG20070218</org_study_id>
    <nct_id>NCT01054482</nct_id>
  </id_info>
  <brief_title>Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Locally Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is to compare neoadjuvant chemotherapy with concurrent chemoradiotherapy
      in patients with locally advanced non-small cell lung cancer (NSCLC) to address optimal
      induction strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Management of locally advanced non-small cell lung cancer (NSCLC) remains a challenge. Both
      local relapses and distant metastases are frequent, with 5-year survival of 3-17% for
      inoperable disease. Staging has historically subdivided stage III disease into clinical stage
      IIIA, thought to be potentially amenable to surgery, and stage IIIB, treated by defi nitive
      radiotherapy or radiochemotherapy. This phase II trial is to compare neoadjuvant chemotherapy
      with concurrent chemoradiotherapy in patients with locally advanced NSCLC to address optimal
      induction strategy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the time to recurrence</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pathologic complete response rate and the complete resection rate</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate toxicities</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pre-operative chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op &amp; Post-Op (total 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-operative concurrent chemoradiation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-operative chemotherapy</intervention_name>
    <description>Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op &amp; Post-Op (total 4 cycles)</description>
    <arm_group_label>Pre-operative chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-operative concurrent chemoradiation therapy</intervention_name>
    <description>Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op &amp; Post-Op: 2 cycles (total 4 cycles).
Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx</description>
    <arm_group_label>Pre-operative concurrent chemoradiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologic diagnosis of non small-cell lung cancer

          -  Clinical stage IIIA and/or IIIB without pleural effusion

          -  ECOG functional status 0 or 1

          -  No renal function alteration (GFR &gt;50%)

          -  No hepatic function alteration (ALT and AST less than 2 times its normal value)

          -  Leucocytes more than 2,000/mcl

          -  Hemoglobin more than 10mg/dL

          -  Platelets more than 100,000/mcl

        Exclusion Criteria:

          -  Active uncontrolled infection.

          -  Serious concomitant disorders that would compromise the safety of patient or
             compromise the patient's ability to tolerate therapy.

          -  MI within preceding 6 months or symptomatic heart disease including unstable angina,
             congestive heart failure, or uncontrolled arrhythmia.

          -  Significant neurological or mental disorder.

          -  Second primary malignancy.

          -  Pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxing He, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianxing He, MD, FACS</last_name>
    <phone>+86-20-83337792</phone>
    <email>drjianxing.he@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daoyuan Wang, MD</last_name>
    <phone>+86-20-83337792</phone>
    <email>ghealth2008@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenlong Shao, MD</last_name>
      <phone>+86-20-83337750</phone>
      <phone_ext>7040</phone_ext>
      <email>myfriends2003@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Daoyuan Wang, MD</last_name>
      <phone>+86-20-83337750</phone>
      <phone_ext>7040</phone_ext>
      <email>ghealth2008@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianxing He, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>The First Affiliated Hospital of Guangzhou Medical College</name_title>
    <organization>Guangzhou Medical College</organization>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>neoadjuvant chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

